BioSpace News Archive

OliX Pharmaceuticals, Inc. (KOSDAQ: 226950), a leading developer of RNAi therapeutics, announced today that the Company has secured positive effects of OLX702A, an investigational GalNAc-asiRNA therapeutics for the treatment of nonalcoholic steatohepatitis (NASH), on liver fat content in a non-human primate NASH model.

Wugen, Inc. today announced an upcoming presentation outlining the unique molecular characteristics of WU-NK-101, the company’s lead memory natural killer (NK) cell therapy product, at the upcoming Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting taking place November 8-12, 2022 in Boston, MA.

Charles River Laboratories International, Inc. announced the expansion of its cell therapy contract development and manufacturing facility in Memphis, Tenn.

Avilar Therapeutics, a biopharmaceutical company focused on extracellular protein degradation, today presented new preclinical proof-of-concept data demonstrating the degradation of extracellular proteins using its asialoglycoprotein receptor (ASGPR) targeting chimera (ATAC) platform at the Keystone Symposium on Targeted Protein Degradation being held in Vancouver, British Columbia.

Astria Therapeutics, Inc. (NASDAQ:ATXS) today announced that it will share preclinical data for STAR-0215 in a presentation titled “Modeling and Simulation Predicts Robust HAE Attack Suppression with Every Three Month Dosing of STAR-0215” at the 2022 American College of Allergy, Asthma and Immunology (ACAAI) Annual Scientific Meeting in Louisville, Kentucky.

Bicara Therapeutics will present data at the Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting, being held in Boston, Massachusetts from November 8-12, 2022.

Adicet Bio Showcases Preclinical Data for Four New Pipeline Programs at The Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting.

Incyte (Nasdaq:INCY) today announced that abstracts featuring data from its oncology portfolio will be presented at the upcoming Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting, held November 8-12, 2022, in Boston and virtually.

Pionyr Immunotherapeutics, Inc. will present pre-clinical data showing the potential for its PY265 program to treat solid tumors, as a single agent and in combination with checkpoint inhibitor (CPI) therapy.

Calidi Biotherapeutics, Inc. today announced the presentation of new pre-clinical data from the the company’s SuperNova-1 (SNV1) platform at the upcoming Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting, taking place in Boston, Massachusetts and virtually, November 8-12, 2022.